AWM
ALNY icon

Avior Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Avior Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-33
Closed -$7.76K – 791
2024
Q4 		$7.76K Buy
33
+28
+560% +$7.36K ﹤0.01% 1705
2024
Q3 		$1.38K Sell
5
-4
-44% -$1.04K ﹤0.01% 2036
2024
Q2 		$2.19K Hold
9
– – ﹤0.01% 1927
2024
Q1 		$1.34K Buy
+9
New +$1.5K ﹤0.01% 2341
2020
Q2 		– Sell
-1,420
Closed -$154K – 888
2020
Q1 		$154K Sell
1,420
-1,070
-43% -$124K 0.03% 378
2019
Q4 		$286K Sell
2,490
-390
-14% -$38.9K 0.05% 331
2019
Q3 		$231K Sell
2,880
-1,560
-35% -$123K 0.04% 346
2019
Q2 		$322K Buy
4,440
+1,380
+45% +$106K 0.06% 280
2019
Q1 		$285K Buy
3,060
+1,330
+77% +$111K 0.06% 284
2018
Q4 		$126K Buy
1,730
+650
+60% +$50K 0.03% 401
2018
Q3 		$95K Sell
1,080
-310
-22% -$31.2K 0.02% 440
2018
Q2 		$137K Buy
+1,390
New +$138K 0.03% 412

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Avior Wealth Management's ALNY Position: Q1 2025 in Review

Avior Wealth Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2025, closing a stake of 33 shares — an estimated $7.76K sold.

Avior Wealth Management first reported a position in ALNY in Q2 2018 and held it in 12 quarters. The position peaked at $322K in Q2 2019. 627 funds tracked by Wall St. Rank hold ALNY as of Q1 2025.

  • Avior Wealth Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Avior Wealth Management sold 33 Alnylam Pharmaceuticals shares in Q1 2025, an estimated $7.76K.
  • Avior Wealth Management first reported a position in Alnylam Pharmaceuticals in Q2 2018 and held it in 12 quarters.
  • Avior Wealth Management's Alnylam Pharmaceuticals position peaked at $322K in Q2 2019.
  • 627 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2025.

Based on Avior Wealth Management's 13F filing for Q1 2025, filed 21 Apr 2025.